US20110070225A1 - Beta antibody parenteral formulation - Google Patents

Beta antibody parenteral formulation Download PDF

Info

Publication number
US20110070225A1
US20110070225A1 US12/448,190 US44819007A US2011070225A1 US 20110070225 A1 US20110070225 A1 US 20110070225A1 US 44819007 A US44819007 A US 44819007A US 2011070225 A1 US2011070225 A1 US 2011070225A1
Authority
US
United States
Prior art keywords
formulation
histidine
abeta antibody
formulation according
tween
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/448,190
Other languages
English (en)
Inventor
Pierre Goldbach
Hanns-Christian Mahler
Robert Mueller
Christine Wurth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110070225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOLDBACH, PIERRE, MAHLER, HANNS-CHRISTIAN, MUELLER, ROBERT, WURTH, CHRISTINE
Publication of US20110070225A1 publication Critical patent/US20110070225A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Definitions

  • the present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation thereof. Furthermore, corresponding uses are described.
  • the invention relates to a stable pharmaceutical parenteral Abeta antibody pharmaceutical formulation comprising:
  • the present invention relates to an Abeta antibody formulation wherein the comprised Abeta antibodies (or mixtures thereof) are capable of specifically binding the amyloid-beta peptide.
  • Antibodies that specifically bind Abeta are known in the art.
  • Specific examples of Abeta antibody that can be used in the formulation according to the invention have been described in the published PCT patent application WO 03/070760 and especially in the claims, the content of which is incorporated herein by reference.
  • amyloid-beta peptide which is also termed “amyloid ⁇ ”, “A ⁇ ”, “A ⁇ 4” or “ ⁇ -A4” and, in particular in context of this invention “Abeta”, is a main component of the extracellular neuritic plaques that are associated with amyloidogenic diseases such as Alzheimer's disease; see Selkoe (1994), Ann. Rev. Cell Biol. 10, 373-403, Koo (1999), PNAS Vol. 96, pp. 9989-9990, U.S. Pat. No. 4,666,829 or Glenner (1984), BBRC 12, 1131.
  • This amyloid ⁇ is derived from “Alzheimer precursor protein/ ⁇ -amyloid precursor protein” (APP).
  • APPs are integral membrane glycoproteins (see Sisodia (1992), PNAS Vol. 89, pp. 6075) and are endoproteolytically cleaved within the Abeta sequence by a plasma membrane protease, ⁇ -secretase (see Sisodia (1992), loc. cit.).
  • amyloid- ⁇ comprising either 39 amino acids (A ⁇ 39), 40 amino acids (A ⁇ 40), 42 amino acids (A ⁇ 42) or 43 amino acids (A ⁇ 43); see Sinha (1999), PNAS 96, 11094-1053; Price (1998), Science 282, 1078 to 1083; WO 00/72880 or Hardy (1997), TINS 20, 154.
  • a ⁇ has several naturally occurring forms, whereby the human forms are referred to as the above mentioned A ⁇ 39, A ⁇ 40, A ⁇ 41, A ⁇ 42 and A ⁇ 43.
  • the most prominent form, A ⁇ 42 has the amino acid sequence (starting from the N-terminus): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 3).
  • a ⁇ 41, A ⁇ 40, A ⁇ 39 the C-terminal amino acids A, IA and VIA are missing, respectively.
  • an additional threonine residue is comprised at the C-terminus of the above depicted sequence (SEQ ID NO: 3).
  • Antibody molecules as part of the group of protein pharmaceuticals, are very susceptible to physical and chemical degradation, such as denaturation and aggregation, deamidation, oxidation and hydrolysis.
  • Protein stability is influenced by the characteristics of the protein itself, e.g. the amino acid sequence, and by external influences, such as temperature, solvent pH, excipients, interfaces, or shear rates. So, it is important to define the optimal formulation conditions to protect the protein against degradation reactions during manufacturing, storage and administration.
  • Andya et al. (U.S. Pat. No. 6,267,958, U.S. Pat. No. 6,85,940) describe a stable lyophilized formulation of an antibody, which is reconstituted with a suitable diluent volume to achieve the required concentration.
  • the formulation comprises a lyoprotectant, a buffer and a surfactant.
  • One object of the present invention is to provide a formulation of an Abeta antibody or of mixtures of such antibodies, which is/are concentrated to the required concentration by reconstitution of a lyophilized formulation with a suitable volume or by removing the solvent by an ultrafiltration process.
  • the formulation demonstrates sufficient stability during manufacturing, storage and administration.
  • antibodies show an unpredictable viscosity-concentration profile.
  • the presented formulation provides equal or better stability of an Abeta human antibody during storage and has a viscosity, which is suitable for the subcutaneous or intramuscular administration route.
  • Abeta antibodies that are useful in the present invention are immunoglobulin molecules, e.g. IgG molecules.
  • IgGs are characterized in comprising two heavy and two light chains (illustrated e.g. in FIG. 1 ) and these molecules comprise two antigen binding sites.
  • Said antigen binding sites comprise “variable regions” consisting of parts of the heavy chains (VH) and parts of the light chains (VL).
  • the antigen-binding sites are formed by the juxtaposition of the VH and VL domains.
  • the parenteral formulation of the present invention comprises Abeta antibody (or mixture of such antibodies) in which in at least one of the variable regions in the heavy chain of said antibodies comprises a N-glycosylation.
  • the glycosylated asparagine (Asn) in the variable region of the heavy chain (VH) may be in the complementarity determining region 2 (CDR2 region), said glycosylated asparagine (Asn) may be on position 52 in the variable region of the heavy chain (VH) as shown in SEQ ID NO: 1.
  • the term “mono-glycosylated antibody” relates to an antibody molecule comprising an N-glycosylation in one (V H )-region of an individual antibody molecule“; see also FIG. 1 .
  • the term “double-glycosylation antibody” defines an antibody molecule which is N-glycosylated on both variable regions of the heavy chain” ( FIG. 1 ).
  • Antibody molecules which lack a N-glycosylation on both heavy chain (V H )-domains are named “non-glycosylated antibodies” ( FIG. 1 ).
  • the mono-glycosylated antibody, the double-glycosylated antibody and the non-glycosylated antibody may comprise the identical amino acid sequences or different amino acid sequences.
  • the mono-glycosylated antibody and the double-glycosylated antibody are herein referred to as “glycosylated antibody isoforms”.
  • a purified antibody molecule characterized in that at least one antigen binding site comprises a glycosylation in the variable region of the heavy chain (VH) is a mono-glycosylated antibody which is free of or to a very low extent associated with an isoform selected from a double-glycosylated antibody and a non-glycosylated antibody, i.e. a “purified mono-glycosylated antibody”.
  • a double-glycosylated antibody in context of this invention is free of or to a very low extent associated with an isoform selected from a mono-glycosylated antibody and a non-glycosylated antibody, i.e. a “purified double-glycosylated antibody”.
  • the formulations according to this invention may contain mono-glycosylated or double-glycosylated or non-glycosylated antibodies, or specifically defined mixtures thereof.
  • the antibody mixtures or antibody pools provided herein may comprise 50% mono-glycosylated and 50% double-glycosylated antibodies as defined herein. However, also envisaged are the ratios of 30/70 to 70/30. Yet, the person skilled in the art is aware that also other ratios are envisaged in the antibody mixtures of this invention. For example, also 10/90 or 90/10, 20/80 or 80/20 as well as 40/60 or 60/40 may be employed in context of this invention.
  • a particular useful ratio in the antibody mixtures comprised in the formulation of the invention comprises double-glycosylated and mono-glycosylated antibody as defined herein above is a ratio from 40/60 to 45/55.
  • the term “which is free of or to a very low extent” denotes the complete absence of the respective other (glycosylation) isoforms or a presence of another (glycosylated) isoform in a concentration of at the most 10%, e.g. at the most 5%, e.g. at the most 4%, e.g. at the most 3%, e.g. at the most 2%, e.g. at the most 1%, e.g. at the most 0.5%, e.g. at the most 0.3%, e.g. at the most 0.2%.
  • antibody(ies) is used herein synonymously with the term “antibody molecule(s)” and comprises, in the context of the present invention, antibody molecule(s) like full immunoglobulin molecules, e.g. IgMs, IgDs, IgEs, IgAs or IgGs, like IgG1, IgG2, IgG2b, IgG3 or IgG4 as well as to parts of such immunoglobulin molecules, like Fab-fragments, Fab′-fragments, F(ab)2-fragements, chimeric F(ab)2 or chimeric Fab' fragments, chimeric Fab-fragments or isolated VH- or CDR-regions (said isolated VH- or CDR-regions being, e.g.
  • antibody also comprises known isoforms and modifications of immunoglobulins, like single-chain antibodies or single chain Fv fragments (scAB/scFv) or bispecific antibody constructs, said isoforms and modifications being characterized as comprising at least one glycosylated VH region as defined herein.
  • scAB/scFv single chain Fv fragments
  • bispecific antibody constructs said isoforms and modifications being characterized as comprising at least one glycosylated VH region as defined herein.
  • a specific example of such an isoform or modification may be a sc (single chain) antibody in the format VH-VL or VL-VH, wherein said VH comprises the herein described glycosylation.
  • bispecific scFvs are envisaged, e.g.
  • the present invention also relates to parenteral formulations of Abeta antibodies that comprise “mixtures” of antibodies/antibody molecules. A particular “mixture” of said antibodies is described above, namely a mixture of “mono” and “double”-glycosylated antibodies directed against Abeta.
  • Antibody fragments also comprises such fragments which per se are not able to provide effector functions (ADCC/CDC) but provide this function in a manner according to the invention after being combined with appropriate antibody constant domain(s).
  • the Abeta antibody(ies) that may be comprised in the inventive formulation(s) are, inter alia, recombinantly produced Abeta antibody(ies). These may be produced in a mammalian cell-culture system, e.g. in CHO cells. Such mammalian cell culture systems are particular useful in the preparation of Abeta antibodies or Abeta antibodies/antibody molecules that are glycosylated like the specific herein exemplified Abeta antibody that comprises a N-glycosylation in the variable region.
  • the antibody molecules may be further purified by a sequence of chromatographic and filtration steps e.g. in order to purify the specific glycosylated antibody isoforms as described herein below.
  • the terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of a single amino acid composition. Accordingly, the term “human monoclonal antibody” refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences. In one embodiment, the human monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a transgenic non-human animal, e.g. a transgenic mouse, having a genome comprising a human heavy chain transgene and a light human chain transgene fused to an immortalized cell.
  • a transgenic non-human animal e.g. a transgenic mouse
  • chimeric antibody refers to a monoclonal antibody comprising a variable region, i.e., binding region, from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques.
  • Chimeric antibodies comprising a murine variable region and a human constant region are especially preferred.
  • Such murine/human chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding murine immunoglobulin variable regions and DNA segments encoding human immunoglobulin constant regions.
  • Other forms of “chimeric antibodies” encompassed by the present invention are those in which the class or subclass has been modified or changed from that of the original antibody.
  • Such “chimeric” antibodies are also referred to as “class-switched antibodies.”
  • Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques now well known in the art. See, e.g., Morrison, S. L., et al., Proc. Natl. Acad Sci. USA 81 (1984) 6851-6855; U.S. Pat. Nos. 5,202,238 and 5,204,244.
  • humanized antibody refers to antibodies in which the framework or “complementarity determining regions” (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin.
  • CDR complementarity determining regions
  • a murine CDR is grafted into the framework region of a human antibody to prepare the “humanized antibody.” See, e.g., Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, M.S., et al., Nature 314 (1985) 268-270.
  • Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric and bifunctional antibodies.
  • human antibody is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
  • the variable heavy chain is preferably derived from germline sequence DP-50 (GenBank LO6618) and the variable light chain is preferably derived from germline sequence L6 (GenBank X01668).
  • the constant regions of the antibody are constant regions of human IgG1 type. Such regions can be allotypic and are described by, e.g., Johnson, G., and Wu, T. T., Nucleic Acids Res. 28 (2000) 214-218 and the databases referenced therein and are useful as long as the properties of induction of ADCC and preferably CDC according to the invention are retained.
  • recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell such as an SP2-0, NS0 or CHO cell (like CHO K1) or from an animal (e.g. a mouse) that is transgenic for human immunoglobulin genes or antibodies expressed using a recombinant expression vector transfected into a host cell.
  • recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences in a rearranged form.
  • the recombinant human antibodies according to the invention have been subjected to in vivo somatic hypermutation.
  • the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • binding refers to antibody binding to Abeta with an affinity of about 10 ⁇ 13 to 10 ⁇ 8 M (K D ), preferably of about 10 ⁇ 13 to 10 ⁇ 9 M.
  • the “constant domains” are not involved directly in binding the antibody to an antigen but are involved in the effector functions (ADCC, complement binding, and CDC).
  • the constant domain of an antibody according to the invention is of the IgG1 type. Human constant domains having these characteristics are described in detail by Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), and by Brüggemann, M., et al., J. Exp. Med. 166 (1987) 1351-1361; Love, T. W., et al., Methods Enzymol. 178 (1989) 515-527.
  • variable region denotes each of the pair of light and heavy chains which is involved directly in binding the antibody to the antigen.
  • the domains of variable human light and heavy chains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three “hypervariable regions” (or complementarity determining regions, CDRs).
  • the framework regions adopt a ⁇ -sheet conformation and the CDRs may form loops connecting the ⁇ -sheet structure.
  • the CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site.
  • the antibody heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
  • hypervariable region or “antigen-binding portion of an antibody” when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the hypervariable region comprises amino acid residues from the “complementarity determining regions” or “CDRs”.
  • “Framework” or “FR” regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chains of an antibody comprise from N- to C-terminus the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • CDR3 of the heavy chain is the region which contributes most to antigen binding.
  • CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those residues from a “hypervariable loop”.
  • the formulation of this invention may, inter alia, comprise “stabilizers”, “lyoprotectants”, “sugars”, “amino acids”, “polyols”, “antioxidants”, “preservatives”, “surfactants”, “buffers” and/or “tonicity agents”.
  • stabilizer denotes a pharmaceutical acceptable excipient, which protects the active pharmaceutical ingredient and/or the formulation from chemical and/or physical degradation during manufacturing, storage and application. Chemical and physical degradation pathways of protein pharmaceuticals are reviewed by Cleland, J. L., M. F. Powell, et al. (1993). “The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.” Crit Rev Ther Drug Carrier Syst 10(4): 307-77, Wang, W. (1999). “Instability, stabilization, and formulation of liquid protein pharmaceuticals.” Int J Pharm 185(2): 129-88., Wang, W. (2000).
  • Stabilizers include but are not limited to sugars, amino acids, polyols, surfactants, antioxidants, preservatives, cyclodextrines, e.g.
  • stabilizers can be present in the formulation in an amount of about 10 to about 500 mM, preferably in an amount of about 10 to about 300 mM and more preferably in an amount of about 100 mM to about 300 mM.
  • Lyoprotectant denotes pharmaceutical acceptable excipients, which protects the labile active ingredient (e.g. a protein) against destabilizing conditions during the lyophilisation process, subsequent storage and reconstitution. Lyoprotectants comprise but are not limited to the group consisting of sugars, polyols (such as e.g. sugar alcohols) and amino acids.
  • Preferred lyoprotectants can be selected from the group consisting of: sugars such as sucrose, trehalose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, and raffinose neuraminic acid and galactosamine, amino sugars such as glucosamine, N-Methylglucosamine (“Meglumine”), polyols such as mannitol, and amino acids such as arginine. Lyoprotectants are generally used in an amount of about 10 to 500 mM, preferably in an amount of about 10 to about 300 mM and more preferably in an amount of about 100 to about 300 mM.
  • sugars such as sucrose, trehalose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, and raffinose neuraminic acid and galactosamine
  • amino sugars such as gluco
  • sugar denotes a pharmaceutically acceptable carbohydrate used generally in an amount of about 10 mM to about 500 mM, preferably in an amount of about 10 to about 300 mM and more preferably in an amount of about 100 to about 300 mM.
  • Suitable sugars comprise but are not limited to trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-Methylglucosamine (so-called “Meglumine”), galactosamine and neuraminic acid.
  • Preferred sugars are sucrose and trehalose and more preferably sucrose.
  • amino acid as used herein in the context of the pharmaceutical parenteral formulation denotes a pharmaceutical acceptable organic molecule possessing an amino moiety located at ⁇ -position to a carboxylic group.
  • Amino acids comprise but not limited to arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof.
  • Amino acids are generally used in an amount of about 10 to 500 mM, preferably in an amount of about 10 to about 300 mM and more preferably in an amount of about 100 to about 300 mM.
  • polyols denotes pharmaceutically acceptable alcohols with more than one hydroxy group.
  • Polyols can be used in an amount of about 10 mM to about 500 mM, preferably in an amount of about 10 to about 300 and more preferably in an amount of about 100 to about 300 mM.
  • Suitable polyols comprise to but are not limited to mannitol, sorbitol, glycerine, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol, and combinations thereof.
  • antioxidant denotes pharmaceutically acceptable excipients, which prevent oxidation of the active pharmaceutical ingredient.
  • Antioxidants can be used in an amount of about 1 to about 100 mM, preferably in an amount of about 5 to about 50 mM and more preferably in an amount of about 5 to about 20 mM.
  • Antioxidants comprise but are not limited to ascorbic acid, glutathione, cysteine, methionine, citric acid, EDTA, and combinations thereof.
  • preservative denotes pharmaceutically acceptable excipients, which prevent the growth of microorganism in the formulation.
  • a preservative to a multi-dose formulation protects the formulation against microbial contamination.
  • Preservatives are generally used in an amount of about 0.001 to about 2%(w/v).
  • Preservatives comprise but are not limited to ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof.
  • surfactant denotes a pharmaceutically acceptable surfactant.
  • the amount of surfactant is described a percentage expressed in weight/volume percent (w/v %).
  • Suitable pharmaceutically acceptable surfactants comprise but are not limited to the group of polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer, Pluronic)., and sodium dodecyl sulphate (SDS).
  • Preferred polyoxyethylenesorbitan-fatty acid esters are polysorbate 20,(sold under the trademark Tween20TM) and polysorbate 80 (sold under the trademark Tween 80TM).
  • Preferred polyethylene-polypropylene copolymers are those sold under the names Pluronic® F68 or Poloxamer 188TM.
  • Preferred Polyoxyethylene alkyl ethers are those sold under the trademark BrijTM.
  • Preferred alkylphenolpolyoxyethylene ethers are sold under the tradename Triton-X.
  • polysorbate 20 Tween 20TM
  • polysorbate 80 Tween 80TM
  • concentration range of about 0.001 to about 1%, preferably of about 0.005 to about 0.1% and still preferably about 0.01% to about 0.04% w/v.
  • buffer denotes a pharmaceutically acceptable excipient, which stabilizes the pH of a pharmaceutical preparation.
  • Suitable buffers are well known in the art and can be found in the literature.
  • Preferred pharmaceutically acceptable buffers comprise but are not limited to histidine-buffers, citrate-buffers, succinate-buffers and phosphate-buffers.
  • Still preferred buffers comprise L-histidine or mixtures of L-histidine and L-histidine hydrochloride with pH adjustment with an acid or a base known in the art.
  • histidine-buffers are generally used in an amount of about 1 mM to about 100 mM, preferably of about 5 mM to about 50 mM and still more preferably of about 10-20 mM.
  • the pH can be adjusted at a value comprising about 4.0 to about 7.0 and preferably about 5.0 to about 6.0 and still preferably about 5.5 with an acid or a base known in the art, e.g., hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid and citric acid, sodium hydroxide and potassium hydroxide
  • tonicity agents denotes pharmaceutically acceptable tonicity agents.
  • Tonicity agents are used to modulate the tonicity of the formulation.
  • the formulation can be hypotonic, isotonic or hypertonic. Isotonicity is generally relates to the osmotic pressure relative of a solution usually relative to that of human blood serum.
  • the formulation according to the invention can be hypotonic, isotonic or hypertonic but will preferably be isotonic. In a concern for clarity it is once more emphasized that an isotonic formulation is liquid or liquid reconstituted from a solid form, e.g.
  • Suitable isotonicity agents comprise but are not limited to sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars, in particular glucose as defined herein as well as combinations thereof. Tonicity agents are used in an amount of about 5 mM to about 500 mM.
  • liquid as used herein in connection with the formulation according to the invention denotes a formulation which is liquid at a temperature of at least about 2 to about 8° C. under standard pressure.
  • lyophilizate as used herein in connection with the formulation according to the invention denotes a formulation which is manufactured by freeze-drying methods known in the art per se.
  • the solvent e.g. water
  • the lyophilizate has usually a residual moisture of about 0.1 to 5% (w/w) and is present as a powder or a physical stable cake.
  • the lyophilizate is characterized by a fast dissolution after addition of a reconstitution medium.
  • the term “reconstituted formulation” as used herein in connection with the formulation according to the invention denotes a formulation which is lyophilized and re-dissolved by addition of reconstitution medium.
  • the reconstitution medium comprises but is not limited to water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solutions (e.g. 0.9% (w/v) NaCl), glucose solutions (e.g. 5% glucose), surfactant containing solutions (e.g. 0.01% polysorbate 20), a pH-buffered solution (e.g. phosphate-buffered solutions) and combinations thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solutions e.g. 0.9% (w/v) NaCl
  • glucose solutions e.g. 5% glucose
  • surfactant containing solutions e.g. 0.01% polysorbate 20
  • a pH-buffered solution e.g. phosphate-buffered solutions
  • stable formulation denotes a formulation, which preserves its physical and chemical integrity during manufacturing, storage and application.
  • Various analytical techniques for evaluating protein stability are available and reviewed in Reubsaet, J. L., J. H. Beijnen, et al. (1998). “Analytical techniques used to study the degradation of proteins and peptides: chemical instability”. J Pharm Biomed Anal 17(6-7): 955-78 and Wang, W. (1999). “Instability, stabilization, and formulation of liquid protein pharmaceuticals.” Int J Pharm 185(2): 129-88.
  • Stability can be evaluated by storage at selected climate conditions for a selected time period, by applying mechanical stress such as shaking at a selected shaking frequency for a selected time period, by irradiation with a selected light intensity for a selected period of time, or by repetitive freezing and thawing at selected temperatures.
  • pharmaceutically acceptable as used herein in connection with the formulation according to the invention denotes a formulation which is in compliance with the current international regulatory requirements for pharmaceuticals.
  • a pharmaceutical acceptable formulation contains excipients which are generally recognized for the anticipated route of application and concentration range as safe. In addition, it should provide sufficient stability during manufacturing, storage and application. Especially a formulation for a parenteral route of application should fulfill the requirements isotonicity and euhydric pH in comparison to the composition of human blood.
  • the invention relates to a stable pharmaceutical parenteral Abeta antibody formulation comprising:
  • the Abeta antibody concentration ranges from about 1 to about 250 mg/mL, preferably from about 50 mg/mL to about 200 mg/mL and more preferably from about 150 mg/mL to about 200 mg/mL.
  • concentrations as indicated herein relate to the concentration in a liquid or in a liquid that is accurately reconstituted from a solid form. Accordingly, the lyophilized formulations as described herein can be reconstituted from a lyophilizate in such way that the resulting reconstituted formula comprises the respective constituents in the concentrations described herein.
  • the stable lyophilizates as described herein may also be reconstituted using such an amount of reconstitution medium that the resulting reconstituted formulation is either more concentrated or less concentrated.
  • the lyophilizate of “Formulation A” as described herein in Table 2 may be reconstituted in such way that the resulting reconstituted formulation is further diluted to comprise e.g. 20 mg/mL Abeta antibody, 5.3 mM L-histidine, 66.7 mM Sucrose and 0.011% polysorbate 20; see Formulation R of Table 2.
  • the formulation according to the invention can be in a liquid form, a lyophilized form or in a liquid form reconstituted from a lyophilized form.
  • the formulation of the invention in a lyophilized form or in a liquid from reconstituted from a lyophilized form, it can comprise at least one lyoprotectant as stabilizer.
  • the formulation according to the invention can be administered by intravenous (i.v.), subcutaneous (s.c.) or any other parenteral administration means such as those known in the pharmaceutical art.
  • the formulation according to the invention is preferably administered by subcutaneous ways.
  • the formulation according to the invention can be prepared by methods known in the art, such as ultrafiltration-diafiltration, dialysis, addition and mixing, lyophilisation, reconstitution, and combinations thereof. Examples of preparations of formulations according to the invention can be found hereinafter.
  • the Abeta antibody comprised in the pharmaceutical parenteral formulation of the present invention may comprise or have the variable region as defined in SEQ ID NO: 1:
  • the exemplified Abeta antibody comprising SEQ ID NO: 1 as described herein may also comprise a light chain, said light chain may comprise or have the following amino acid sequence:
  • Abeta antibody A relates to the exemplified Abeta antibody comprising a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2.
  • the term “mono-glycosylated antibody(ies)”, as used herein, relates to antibody molecules comprising an N-glycosylation in one (VH)-region of an individual antibody molecule, e.g. of an immunoglobulin, e.g. an IgG, e.g. of an IgG1.
  • said “mono-glycosylated form” comprises a glycosylation on one variable region of the heavy chain e.g. at position asparagine “Asn 52” of the herein described “Abeta antibody A”.
  • This “mono-glycosylated IgG1 -form or mono-glycosylated isoform” may also comprise, as illustrated herein, the glycosylation in the well conserved glycosylation site in the Fc-part, for example asparagine Asn 306 in the non-variable Fc-part of the herein exemplified “Abeta antibody A”.
  • double-glycosylated antibody(ies) in the meaning of this invention comprises the herein defined glycosylation on both variable regions of the heavy chain (VH)-region.
  • this “double glycosylated form” comprises a glycosylation on the variable region of both heavy chains, e.g. at position asparagine Asn 52 of the herein exemplified “Abeta antibody A”.
  • This “double-glycosylated IgG1-form or double-glycosylated isoform” may also comprise, as illustrated herein, the glycosylation in the well conserved glycosylation site in the non-variable/constant Fc-part, in particular on position 306 of the exemplified “Abeta antibody A”.
  • Appended FIG. 1 illustrates corresponding antibody molecules.
  • Antibodies devoid of such a post-translational modification in the variable region e.g. in both variable regions of the heavy chain (both (VH)-regions) are, in context of this invention considered as a “non-glycosylated form”, comprising no glycosylation in the variable region of the heavy chain.
  • this “non-glycosylated form” may nevertheless comprise (a) glycosylation(s) in the constant region (C-region) of the antibody, for example, and most commonly at the well conserved glycosylation site of the Fc-part, in particular the asparagine (Asn) 306 in the non-variable/constant Fc-part as defined herein; see also SEQ ID NO: 1.
  • the pharmaceutical parenteral formulations of the invention may comprise the exemplary “Abeta antibody A” as defined herein above and as illustrated in the appended examples. Accordingly, said pharmaceutical parenteral formulations comprising Abeta antibody A may comprise mono-glycosylated Abeta antibody A or double-glycosylated Abeta antibody A or non-glycosylated Abeta antibody A or mixtures thereof as defined above.
  • Purification of glycosylation isoforms of recombinantly expressed Abeta antibody molecules may comprise the steps of:
  • the purification protocol may comprise further steps, like further concentration steps, e.g. diafiltration or analytical steps, e.g. involving analytical columns. It is also envisaged and feasible that particular certain steps are repeated (e.g. two ion exchange chromatography steps may be carried out) or that certain steps (e.g. size exclusion chromatography) may be omitted.
  • Protein A is a group specific ligand which binds to the Fc region of most IgG1 isotypes. It is synthesized by some strains of Staphylococcus aureus and can be isolated therefrom and coupled to chromatographic beads. Several types of gel preparations are available commercially.
  • An example for a protein A column which may be used is a MabSelect (Trademark) column. Ideally the column is equilibrated with 25 mM Tris/HCl, 25 mM NaCl, 5 mM EDTA, the cell culture supernatant is loaded onto the column, the column is washed with 1 M Tris/HCl pH 7.2 and the antibody is eluted at pH 3.2 using 100 mM acetic acid.
  • Cation-exchange chromatography exploits interactions between positively charged groups in a stationary phase and the sample which is in the mobile phase.
  • a weak cation exchanger e.g. CM Toyopearl 650®
  • the following chromatographic steps are performed: After preequilibration with 100 mM acetic acid pH 4, loading of Protein A eluate and washing with 100 mM acetic acid pH 4 the antibody is eluted and fractionated by applying steps of 250 mM sodium acetate (pH 7.8-8.5) and 500 mM sodium acetate (pH 7.8-8.5).
  • the first step a mixture of double-glycosylated isoform fraction and mono-glycosylated isoform fraction are normally eluted
  • using the second step the non-glycosylated isoform fraction is normally eluted.
  • the antibody can be eluted by salt steps: After equilibration of the column with 50 mM acetic acid pH 5.0, loading the Protein A eluate with pH 4 the first elution step using 50 mM acetic acid and 210 mM sodium chloride is performed. Then a second elution step of 50 mM acetic acid and 350 mM sodium chloride is applied.
  • a first salt step a mixture of the double-glycosylated isoform fraction and mono-glycosylated isoform fraction are normally eluted
  • the second salt step the non-glycosylated isoform is normally eluted.
  • the antibody may also be eluted from a strong cation exchanger column (e.g. SP-Sepharose®) by a salt gradient: After preequilibration, loading and washing the column at pH 4.5 a salt gradient is applied from 50 mM MES pH 5.8 to 50 mM MES/1 M sodium chloride pH 5.8.
  • a salt gradient is applied from 50 mM MES pH 5.8 to 50 mM MES/1 M sodium chloride pH 5.8.
  • the double-glycosylated isoform, mono-glycosylated isoform and non-glycosylated isoform fractions are normally eluted separately.
  • double-glycosylated isoform fraction and mono-glycosylated isoform fraction may be pooled to result in the product pool and/or a desired antibody mixture.
  • Further purification of the mixture of double- and mono-glycosylated antibody molecules, e.g. immunoglobulins, may be performed by size exclusion chromatography.
  • An example of a useful column is a Superdex 200® column.
  • Examples of running buffers include histidine/sodium chloride, e.g. 10 mM histidine/125 mM sodium chloride/pH 6, and phosphate buffered saline (PBS).
  • Q Sepharose® is an example for a resin for the anion exchange step.
  • the eluate from the SP chromatography may be threefold diluted with 37,5 mM Tris/HCl pH 7.9 and passed over a Q-Sepharose column pre-equilibrated with 25 mM Tris/83 mM sodium acetate.
  • the flow through is collected, adjusted to pH 5.5 and concentrated by ultrafiltration using e.g. a Hydrosart 30 kD® membrane.
  • the concentrate may be diafiltrated against for example 10 volumes of 20 mM histidine/HCl pH 5.5.
  • antibody isoforms may also comprise (a) further glycosylation(s) in the constant/non-variable part of the antibody molecules, e.g. in the Fc-part of an IgG, e.g. in the Fc-part in an IgG1.
  • Said glycosylation in the Fc-part relates to a well conserved glycosylation, being characterized in located on position Asn306 of the heavy chain, e.g., in accordance with the herein defined SEQ ID NO: 1.
  • the IgG-Fc region of the antibodies comprised in the formulations of this invention may be a homodimer comprised of inter-chain disulphide bonded hinge regions, glycosylated CH2 domains, bearing N-linked oligosaccharide at asparagine 306 (Asn-306) of the CH2 and non-covalently paired CH3 domains.
  • the oligosaccharide of the glycosylation at Asn-306 is of the complex biantennary type and may comprise a core heptasaccharide structure with variable addition of outer arm sugars.
  • the oligosaccharide influences or determines Fc structure and function (Jefferis (1998) Immunol Rev. 163, 50-76). Effector functions, numbering particular specific IgG-Fc/effector ligand interactions have been discussed (Jefferis (2002) Immunol Lett. 82(1-2), 57-65 and Krapp (2003) J Mol Biol. 325(5), 979-89). This conserved Fc-position Asn-306 corresponds to “Asn-297” in the Kabat-system (Kabat (1991) Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda Md.)
  • the formulation of the invention is a liquid or lyophilized formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • FIG. 1 Scheme of double-, mono- and non-glycosylated antibody molecules (immunoglobulins).
  • FIG. 2 Content of monomer as determined by size-exclusion chromatography of Abeta antibody A formulations after start and incubation at 5° C., 25° C./60% rh and 40° C./75% rh for up to 6 months.
  • Antibody preparations are freeze-dried and reconstituted to nominal concentration of 75 mg/mL.
  • FIG. 3 Content of monomer as determined by size-exclusion chromatography of Abeta antibody A formulations after start and incubation at 5° C., 25° C./60% rh and 40° C./75% rh for 3 months.
  • Antibody preparations K, L and N are formulated at 75 mg/mL, whereas preparations O, P and Q are formulated at 150 mg/mL.
  • Liquid and lyophilized drug product formulations for subcutaneous administration according to the invention were developed as follows:
  • Abeta antibody comprising a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2 (“Abeta antibody A” in the context of the present invention) was prepared and obtained as described in WO 03/070760 and was concentrated by ultrafiltration to a concentration of approx. 40 to about 200 mg/mL in a 20 mM histidine buffer at a pH of approx. 5.5. The concentrated solution was then diluted with the formulation buffer (containing sugar (respectively salt or polyol), surfactant and buffer at a pH of approx. pH 5.5) resulting the anticipated antibody concentration of approx.
  • the formulation buffer containing sugar (respectively salt or polyol), surfactant and buffer at a pH of approx. pH 5.5
  • 7.5 mg/mL, 37.5 mg/mL, 75 mg/mL or 150 mg/mL formulated in the final bulk composition e.g. 10 mM L-histidine, 125 mM sucrose, 0.02% Tween 20, at pH 5.5.
  • Abeta antibody A was buffer-exchanged against a diafiltration buffer containing the anticipated buffer and sugar composition and concentrated to an antibody concentration equal or higher than the final concentration of approx. 37.5 mg/mL.
  • the surfactant was added after completion of the ultrafiltration operation as a 100 to 200-fold stock solution to the antibody solution.
  • the concentrated antibody solution was adjusted with a formulation buffer containing the identical excipient composition to the final Abeta antibody A concentration of approx. 37.5 mg/mL.
  • the lyophilization process used for this study included the cooling of the formulation from room temperature to approx 5° C. (pre-cooling) and a freezing step to ⁇ 40° C. at a plate cooling rate of approx. 1 ° C./min, followed by a holding step at ⁇ 40° C. for about 2 hours.
  • the first drying step was performed at a plate temperature of approx. ⁇ 25° C. and a chamber pressure of approx. 80 ⁇ bar for about 62 hours.
  • the second drying step started with a temperature ramp of 0.2° C./min from ⁇ 25° C. to 25° C., followed by a holding step at 25° C. for at least 5 hours at a chamber pressure of approx. 80 ⁇ bar (the applied drying schedule is presented in Table 1.)
  • Lyophilization was carried out in an Usifroid SMH-90 LN2 freeze-dryer (Usifroid, Maurepas, France). All lyophilized cakes in this study had a residual water content of about 0.1 to 1.0% as determined by Karl-Fischer method. The freeze-dried samples were incubated at different temperatures for different intervals of time.
  • the lyophilized formulations were reconstituted to a final volume of 1.2 mL with water for injection (WFI) yielding an isotonic formulation with an antibody concentration of approx. 75 mg/mL and a viscosity of less than 3 mPa ⁇ s.
  • the reconstitution time of the freeze-dried cakes was about 2 to 4 min. Analysis of the reconstituted samples was either performed immediately after reconstitution, or after a 24 hour incubation period of the reconstituted liquid sample at 25° C.
  • the samples were analyzed by 1) UV spectrophotometry, 2) determination of the reconstitution time, 3) Size Exclusion Chromatography (SEC) and 4) method of nephelometry to determine the turbidity of the solution.
  • Size Exclusion Chromatography was used to detect soluble high molecular weight species (aggregates) and low molecular weight hydrolysis products (LMW) in the formulations.
  • the method was performed on a Merck Hitachi 7000 HPLC instrument equipped with a Tosohaas TSK G3000 SWXL column. Intact monomer, aggregates and hydrolysis products are separated by an isocratic elution profile, using 0.2M K 2 HPO 4 /0.25M KCL, pH 7.0 as mobile phase, and were detected at a wavelength of 280 nm.
  • UV spectroscopy used for determination of protein content, was performed on a Varian Cary Bio UV spectrophotometer at 280 nm. Neat protein samples were diluted to approx. 0.5 mg/mL with 20 mM L-histidine, pH 5.5. The protein concentration was calculated according equation 1.
  • Protein ⁇ ⁇ content A ⁇ ( 280 ) - A ⁇ ( 320 ) ⁇ dil . ⁇ factor ⁇ ⁇ ⁇ cm 2 ⁇ / ⁇ mg ⁇ ⁇ d ⁇ ⁇ cm ⁇ Equation ⁇ ⁇ 1
  • the protein concentration was measured with a precision of ⁇ 10%.
  • the UV light absorption at 280 nm was corrected for light scattering at 320 nm and multiplied with the dilution factor, which was determined from the weighed masses and densities of the neat sample and the dilution buffer.
  • the numerator was divided by the product of the cuvette's path length d and the extinction coefficient c.
  • Clarity and the degree of opalescence were measured as Formazin Turbidity Units (FTU) by the method of nephelometry.
  • FTU Formazin Turbidity Units
  • compositions of “Abeta antibody A” drug product formulations according to the invention
  • Composition Formulation (Stability data in Table) Lyophilized Formulations Formulation A 75 mg/mL Abeta antibody A, 20 mM L-histidine, 250 mM Sucrose, 0.04% polysorbate 20, at pH 5.5 Protein Turbidity conc. after Size Exclusion - HPLC after reconst. (*) HMW Monomer LMW reconst. Timepoint (mg/mL) (%) (%) (%) (%) (%) (FTU) Initial 72.8 1.9 96.1 2.0 5.4 24 h at 74.8 1.9 96.0 2.1 5.3 25° C. after reconst. 1 month 74.5 1.7 95.8 2.5 5.4 at 2-8° C.
  • HMW Monomer LMW Turbidity Timepoint (mg/mL) (%) (%) (%) (%) (FTU)
  • HMW Monomer LMW Turbidity Timepoint (mg/mL) (%) (%) (%) (%) (FTU)
  • HMW Monomer LMW Turbidity Timepoint (mg/mL) (%) (%) (%) (%) (FTU)
  • HMW Monomer LMW Turbidity Timepoint (mg/mL) (%) (%) (%) (%) (FTU)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/448,190 2006-11-12 2007-12-11 Beta antibody parenteral formulation Abandoned US20110070225A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06025590.8 2006-12-11
EP06025590 2006-12-11
PCT/EP2007/010825 WO2008071394A1 (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation

Publications (1)

Publication Number Publication Date
US20110070225A1 true US20110070225A1 (en) 2011-03-24

Family

ID=39190366

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/448,190 Abandoned US20110070225A1 (en) 2006-11-12 2007-12-11 Beta antibody parenteral formulation

Country Status (21)

Country Link
US (1) US20110070225A1 (enExample)
EP (1) EP2094729A1 (enExample)
JP (1) JP2010512356A (enExample)
KR (1) KR20090104017A (enExample)
CN (1) CN101553504A (enExample)
AR (1) AR064220A1 (enExample)
AU (1) AU2007331712A1 (enExample)
BR (1) BRPI0721097A2 (enExample)
CA (1) CA2671968A1 (enExample)
CL (1) CL2007003583A1 (enExample)
CR (1) CR10823A (enExample)
EC (1) ECSP099403A (enExample)
IL (1) IL198963A0 (enExample)
MA (1) MA30975B1 (enExample)
MX (1) MX2009006199A (enExample)
NO (1) NO20092586L (enExample)
PE (1) PE20081477A1 (enExample)
RU (1) RU2009126420A (enExample)
TW (1) TW200831133A (enExample)
WO (1) WO2008071394A1 (enExample)
ZA (1) ZA200904014B (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090252724A1 (en) * 2005-12-12 2009-10-08 Hansruedi Loetscher Antibodies Against Amyloid Beta 4 With Glycosylated in the Variable Region
WO2013063284A1 (en) * 2011-10-25 2013-05-02 Onclave Therapeutics Antibody formulations and methods
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20140093512A1 (en) * 2008-09-19 2014-04-03 Hoffmann-La Roche Inc. Pharmaceutical formulation comprising an antibody against p-selectin and a sugar selected from sucrose and trehalose
US10322176B2 (en) 2002-03-01 2019-06-18 Immunomedics, Inc. Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10941205B2 (en) 2015-10-02 2021-03-09 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
US11180559B2 (en) 2005-03-03 2021-11-23 Immunomedics, Inc. Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
CN114616249A (zh) * 2019-10-31 2022-06-10 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2445590T3 (es) 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
KR20170116193A (ko) * 2008-06-20 2017-10-18 노파르티스 아게 응집이 감소된 면역글로불린
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
RU2563823C2 (ru) * 2008-11-17 2015-09-20 Дженентек, Инк. Способ и композиция для уменьшения агрегации макромолекул при физиологических условиях
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
BR112012012080B1 (pt) * 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
US10040855B2 (en) * 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
SI2822587T1 (sl) * 2012-03-08 2016-04-29 F. Hoffmann-La Roche Ag Farmacevtska oblika abeta protitelesa
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
HK1225298A1 (zh) 2013-07-23 2017-09-08 Biocon Limited Cd6结合配对体的使用和以其为基础的方法
MD20170055A2 (ro) 2014-10-24 2017-09-30 Merck Sharp & Dohme Corp Co-agonişti ai receptorilor glucagonului şi GLP-1
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104946616A (zh) * 2015-05-12 2015-09-30 骏实生物科技(上海)有限公司 一种用于体外诊断试剂的通用固体稳定剂及其使用方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR102669174B1 (ko) * 2015-08-19 2024-06-10 아스트라제네카 아베 안정한 항-ｉｆｎａｒ1 제형
KR20180037056A (ko) * 2015-09-22 2018-04-10 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
AU2016380988B2 (en) 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用
EP4233901A3 (en) * 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
CN108373494A (zh) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 一种防止重组蛋白质降解的保护技术
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
WO2022072255A1 (en) * 2020-09-30 2022-04-07 Merck Sharp & Dohme Corp. Binding proteins and antigen binding fragments thereof that bind abeta
US20240417451A1 (en) 2023-05-31 2024-12-19 Hoffmann-La Roche Inc. Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090252724A1 (en) * 2005-12-12 2009-10-08 Hansruedi Loetscher Antibodies Against Amyloid Beta 4 With Glycosylated in the Variable Region

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP2335725B1 (en) * 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0606867A2 (pt) * 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
RU2008142359A (ru) * 2006-03-28 2010-05-10 Ф.Хоффманн-Ля Рош Аг (Ch) Композиция человеческого моноклонального антитела к igf-1r

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090252724A1 (en) * 2005-12-12 2009-10-08 Hansruedi Loetscher Antibodies Against Amyloid Beta 4 With Glycosylated in the Variable Region

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322176B2 (en) 2002-03-01 2019-06-18 Immunomedics, Inc. Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
US11180559B2 (en) 2005-03-03 2021-11-23 Immunomedics, Inc. Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
US8906370B2 (en) * 2005-12-12 2014-12-09 Hoffmann-La Roche Inc. Antibodies against amyloid beta 4 with glycosylation in the variable region
US20090252724A1 (en) * 2005-12-12 2009-10-08 Hansruedi Loetscher Antibodies Against Amyloid Beta 4 With Glycosylated in the Variable Region
US20140093512A1 (en) * 2008-09-19 2014-04-03 Hoffmann-La Roche Inc. Pharmaceutical formulation comprising an antibody against p-selectin and a sugar selected from sucrose and trehalose
US9963516B2 (en) 2011-05-02 2018-05-08 Immunomedics, Inc. Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9180205B2 (en) 2011-05-02 2015-11-10 Immunomedics, Inc. Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
US9468689B2 (en) 2011-05-02 2016-10-18 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9683050B2 (en) 2011-05-02 2017-06-20 Immunomedics, Inc. Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
US10517830B2 (en) 2011-10-25 2019-12-31 Prothena Biosciences Limited Antibody formulations and methods
US9089529B2 (en) 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
EA037797B1 (ru) * 2011-10-25 2021-05-21 Протена Байосайенсиз Лимитед Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
WO2013063284A1 (en) * 2011-10-25 2013-05-02 Onclave Therapeutics Antibody formulations and methods
US9884020B2 (en) 2011-10-25 2018-02-06 Prothena Therapeutics Limited Antibody formulations and methods for treating AL amyloidosis
US12252533B2 (en) 2015-06-24 2025-03-18 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US10941205B2 (en) 2015-10-02 2021-03-09 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
US12358997B1 (en) 2015-10-02 2025-07-15 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/anti-human transferrin receptor antibodies
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US12030952B2 (en) 2015-10-02 2024-07-09 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN114616249A (zh) * 2019-10-31 2022-06-10 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂

Also Published As

Publication number Publication date
CL2007003583A1 (es) 2008-07-18
IL198963A0 (en) 2011-08-01
WO2008071394A1 (en) 2008-06-19
NO20092586L (no) 2009-07-17
AR064220A1 (es) 2009-03-18
CR10823A (es) 2009-08-12
RU2009126420A (ru) 2011-01-20
MA30975B1 (fr) 2009-12-01
CA2671968A1 (en) 2008-06-19
CN101553504A (zh) 2009-10-07
EP2094729A1 (en) 2009-09-02
PE20081477A1 (es) 2008-10-18
BRPI0721097A2 (pt) 2014-07-01
MX2009006199A (es) 2009-06-22
ZA200904014B (en) 2010-04-28
AU2007331712A2 (en) 2009-07-30
KR20090104017A (ko) 2009-10-05
AU2007331712A1 (en) 2008-06-19
JP2010512356A (ja) 2010-04-22
ECSP099403A (es) 2009-07-31
TW200831133A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
US20110070225A1 (en) Beta antibody parenteral formulation
US20210000954A1 (en) Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
CA2781467C (en) Formulations of antibody
US20110158987A1 (en) Novel antibody formulation
US20090068196A1 (en) Pharmaceutical formulation of an antibody against IL13Ralpha1
US20150030589A1 (en) Abeta antibody formulation
JP2021178862A (ja) タンパク質製剤
CN112930194B (zh) 抗体制剂
US20240309085A1 (en) Anti-connexin antibody formulations
US20140072559A1 (en) Highly concentrated aqueous protein solution with reduced viscosity
US20090208509A1 (en) Pharmaceutical formulation of an antibody against IL-1R
US20170137535A1 (en) Anti-factor d antibody formulations
US20130251725A1 (en) Anti-P-Selectin Antibody Formulation
US20240368254A1 (en) Accelerated method of making lyophilized protein formualtions
US20230310324A1 (en) Method of making lyophilized protein formulations
CN116688115B (zh) 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
US20250011411A1 (en) Anti-SOST Antibody Pharmaceutical Composition and Use Thereof
HK1136307A (en) Abeta antibody parenteral formulation
EP4548931A1 (en) Anti-pcsk9 antibody preparation and use thereof
CA2966758C (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOLDBACH, PIERRE;MAHLER, HANNS-CHRISTIAN;MUELLER, ROBERT;AND OTHERS;REEL/FRAME:023855/0474

Effective date: 20091207

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION